Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an offering price of $7.25 per share.  The shares will begin trading on The NASDAQ Capital Market on October 25, 2013 under the symbol "SRNE." The gross proceeds to Sorrento from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about October 30, 2013, subject to customary closing conditions. Sorrento has granted the underwriters a 45-day option to purchase up to an additional 622,500 shares of common stock to cover over-allotments, if any.

Sorrento intends to use the net proceeds received from the offering to fund its research and development activities, including its registrational clinical trial of Cynviloq™, for working capital, other general corporate purposes, and possibly acquisitions of other companies, products or technologies.

In connection with its listing on The NASDAQ Capital Market, Sorrento's common stock will cease trading on the OTC QB.   

Aegis Capital Corp. is acting as the sole book-running manager for this offering.

CRT Capital is acting as co-manager for this offering. 

A shelf registration statement and accompanying base prospectus on Form S-3 relating to the shares was filed with the Securities and Exchange Commission and is effective.  A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus supplement, when available, may be obtained from the SEC's web site or the offices of Aegis C
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014   DaVita ... ), one of the nation,s largest and most ... DaVita University Academy – the company,s award-winning, leadership ... Nearly 2,000 DaVita teammates from around the globe ... DaVita University Academy is a two-day one-of-a-kind ...
(Date:10/16/2014)... -- Cepheid (Nasdaq: CPHD ) today reported revenues ... representing growth of 15% from $100.1 million for the ... quarter of 2014 was $(7.2) million, or $(0.10) per ... or $(0.02) per share, in the third quarter of ... of debt discount and transaction costs, and amortization of ...
(Date:10/16/2014)... 16, 2014 Eight finalists, all representing outstanding ... present their proposals for a chance to compete for ... Sheikh Zayed Institute Second Annual Pediatric Surgical Innovation Symposium ... on Friday, Oct. 24, 2014. Selected from ... the US and internationally, the finalists are: ...
Breaking Medicine Technology:DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3Cepheid Reports 2014 Third Quarter Results 2Cepheid Reports 2014 Third Quarter Results 3Cepheid Reports 2014 Third Quarter Results 4Cepheid Reports 2014 Third Quarter Results 5Cepheid Reports 2014 Third Quarter Results 6Cepheid Reports 2014 Third Quarter Results 7Cepheid Reports 2014 Third Quarter Results 8Cepheid Reports 2014 Third Quarter Results 9Cepheid Reports 2014 Third Quarter Results 10Cepheid Reports 2014 Third Quarter Results 11Cepheid Reports 2014 Third Quarter Results 12Cepheid Reports 2014 Third Quarter Results 13Cepheid Reports 2014 Third Quarter Results 14Cepheid Reports 2014 Third Quarter Results 15Cepheid Reports 2014 Third Quarter Results 16Cepheid Reports 2014 Third Quarter Results 17Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4
... Software enables clinical-trial researchers, analysts and managers ... around the world, in real-time, SCOTTSDALE, ... a,part of General Dynamics C4 Systems, introduces ... enables hundreds of,researchers, analysts and managers to ...
... Results, LAUSANNE, Switzerland, April 28 ... specialist,focusing on serious medical conditions, particularly oncology, ... study with Debio 025, a selective,cyclophilin (Cyp) ... C (HCV) effect. Data indicates that Debio ...
Cached Medicine Technology:New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials 2Clinical Update - Debio 025 in Hepatitis C 2Clinical Update - Debio 025 in Hepatitis C 3
(Date:10/18/2014)... New York (PRWEB) October 18, 2014 ... IUD caused women to sustain serious injuries when it ... continue to mount in U.S. courts, Bernstein Liebhard LLP ... the U.S. Judicial Panel on Multidistrict Litigation (JPML) on ... pending in the multidistrict litigation underway in the U.S. ...
(Date:10/18/2014)... One major trend upcoming in this market ... are making efforts to encourage people to donate organs. ... donation process more transparent and easy. , Analysts forecast ... grow at a CAGR of 16.85 percent over the ... major drivers in the market is an increase in ...
(Date:10/18/2014)... 2014 Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ... litigation now underway in Pennsylvania’s Philadelphia Court of ... court documents, 888 product liability claims have been ... patients who allegedly developed serious side effects, ... use of the atypical antipsychotic medication. (In Re: ...
(Date:10/18/2014)... Even determined dieters can fail if they don,t have ... Their new study included 240 obese people. All ... risk factors that increase the risk of heart disease, ... doctors to make lifestyle changes, including improved eating, the ... a clinical trial comparing two dietary interventions: the ...
(Date:10/18/2014)... 18, 2014 As is known to ... webmasters to build websites. Recently, Best Cheap Hosting USA ... announced that Lunarpages Hosting, Bluehost and JustHost are among ... is not so easy to find a good ASP.NET ... hosting features, uptime, server speed and customer support. People ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit Filings Grow, as Claims Pending in Federal Litigation Exceed 1,000, Bernstein Liebhard LLP Reports 4Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 2Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 3Health News:Organ Preservation Solutions Market to Grow at 16.85% CAGR to 2018 Forecast a New Research Report at Sandlerresearch.org 4Health News:Risperdal Lawsuits Mount, as Claims in Pennsylvania Litigation Near 900, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Mount, as Claims in Pennsylvania Litigation Near 900, Bernstein Liebhard LLP Reports 3Health News:Dieters May Be Thwarted by Absence of Healthy Foods 2
... medicine specialist at the University at Buffalo has shown that ... who have low sperm count and low percentage sperm motility. ... a synthetic chemical called AM-1346. After incubation, there was a ... semen, results showed. ,Lani Burkman, Ph.D., and colleagues ...
... Who is too old to receive a lung transplant? ... was there a clear answer when the guidelines for lung ... best clinical data then available,” explained Dr. Philip W. Smith, ... Virginia Health System. ,Since lung transplantation (LTX) was ...
... urination during sleep, and is a major problem for children ... bedwetting (nocturnal enuresis) respond to desmopressin, 30% do not. ... that nighttime urine of these children who do not respond ... that this may possibly be due to an imbalance of ...
... in cities or move there from rural areas are more likely ... suffer from this eating disorder.It is a known fact that she ... teenager. ,Bulimia is an eating disorder in which young ... or purging. This study has observed a startling correlation between cases ...
... 23- year- old gay man died of meningitis C in ... meningitidis.// It occurs rarely in Canada and is usually ... has a record of 10 to 15 per cent fatality ... problems, such as deafness and mental retardation. ,Public ...
... UN population fund report has shown, in India, a majority ... hence vulnerable to HIV.// Therefore, there is a definite need ... woman, as the prevalent male-controlled methods are not even 20 ... HIV/AIDS may be provided by over-the-counter microbicides, which are gels, ...
Cached Medicine News:Health News:New Compound May Improve Fertility in Smokers 2Health News:New Compound May Improve Fertility in Smokers 3Health News:Elderly Lung Transplant Patients More Likely to Survive 2Health News:Elderly Lung Transplant Patients More Likely to Survive 3Health News:Hope For Bedwetting Children 2Health News:Hope For Bedwetting Children 3Health News:Hope For Bedwetting Children 4
Glass Whole Blood Tube with K3EDTA...
... Tissue transglutaminase (tTg) is a ubiquitous ... proteins. Tissue transglutaminase is also the ... the endomysial antibody immunofluorescence (EMA) tests ... Anti-tTg IgA and IgG serologic tests ...
... staff gets the training it needs with ... System and Human Capital Management System in ... requirements for JCAHO and HIPAA, understanding compliance ... or developing skills through continuing education courses, ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: